rg1

Ginsenoside Rg1 (Panaxoside Rg1) is a class of steroid glycosides, and triterpene saponins found exclusively in the plant genus Panax (ginseng). It improves spatial learning and increase hippocampal synaptophysin level in mice, plus demonstrates estrogen-like activity.

Ginsenoside Rg1 (Standard) is a reference standard for research and analysis in studies involving Ginsenoside Rg1. Ginsenoside Rg1 (Panaxoside Rg1) is a class of steroid glycosides, and triterpene saponins found exclusively in the plant genus Panax (ginseng). It improves spatial learning and increase hippocampal synaptophysin level in mice, plus demonstrates estrogen-like activity.

RG13022 (Tyrphostin RG13022) is a tyrosine kinase inhibitor; inhibits the autophosphorylation reaction of the EGF receptor (IC50: 4 μM).

RG14620 (Tyrphostin RG14620) is an epidermal growth factor receptor (EGFR) inhibitor.

BRM/BRG1 ATP Inhibitor-1 is an allosteric dual Brahma homolog (BRM)/SWI/SNF related matrix-associated actin-dependent regulator of chromatin subfamily A member 2 (SMARCA2) and BRG1/SMARCA4 ATPase activity inhibitor (IC50s<0.005 μM).

PROTAC BRM/BRG1 degrader-4 (example 047) is a potent degrader targeting both BRM and BRG1, demonstrating DC50 values of 0.21 nM and 3.4 nM respectively in SW1573 cells.

PROTAC BRM/BRG1 degrader-2 (Example.004) is a potent PROTAC BRM/BRG1 degrading agent exhibiting a DC50 of less than 10 nM and an IC50 of 15 nM in A549 cells.

BRM/BRG1 ligand 3 is a target protein ligand utilized in the synthesis of PROTAC BRM/BRG1 degrader-3.

BRM/BRG1 Ligand 1 is a BRM/BRG1 ligand utilized for the synthesis of PROTAC BRM/BRG1 degrader-1.

PROTAC BRM/BRG1 degrader-1 is a chemical compound that acts as a degrader of PROTAC BRM/BRG1, exhibiting a DC50 range of 10-100 nM (BRM) and > 1 μM (BRG1). This compound is utilized in cancer research.

BRM/BRG1 ligand 2 serves as a target protein ligand for the synthesis of PROTAC BRM/BRG1 degrader-2.

PROTAC BRM/BRG1 degrader-3 (compound 304) is a PROTAC-based degrader of BRM/BRG1. In SW1573 cells, it degrades BRM with a DC50 of less than 1 nM and BRG1 with a DC50 greater than 1 nM. PROTAC BRM/BRG1 degrader-3 exhibits antitumor activity and inhibits the proliferation of A549 cells with an IC50 of 0.6 nM.

RG108 (N-Phthalyl-L-tryptophan) is a DNA methyltransferase inhibitor with an IC50 of 115 nM.

(Rac)-RG108 (NSC401077) is an inhibitor of DNMT1, effectively blocking DNA methyltransferases.

[Des-Arg10]-HOE I40 TFA is a potent antagonist of the bradykinin B1 receptor.

NRG1271 is an orally active inhibitor of the mitochondrial permeability transition pore (mPTP) with the ability to penetrate the blood-brain barrier. It is applicable for research in neurological disorders.

BRM/BRG1 ATP-IN-5 (Compound 6) is an inhibitor of BRG1/BRM. It targets the BAF complex, which plays a role in chromatin regulation and gene expression through ATP-dependent chromatin remodeling. BRM/BRG1 ATP-IN-5 exhibits antitumor potential, particularly in cancers associated with disruptions in the BAF complex.

BRM/BRG1 ATP-IN-6 (Compound 105) is an inhibitor of BRG1/BRM. It acts on the BAF complex, which participates in chromatin regulation and gene expression through ATP-dependent chromatin remodeling. BRM/BRG1 ATP-IN-6 shows antitumor potential, particularly in cancers associated with BAF complex dysfunction.

BRM/BRG1 ATP-IN-7 (Compound Cpd69) functions as a selective dual inhibitor, effectively targeting BRM (SMARCA2) and BRG1 (SMARCA4) with IC50 values of 12 nM and 8 nM, respectively. It shows potential for research in BRM/BRG1-dependent cancers, such as non-small cell lung cancer and Ewing's sarcoma, as well as virus-associated diseases like HPV infection.

BRM/BRG1 ATP-IN-8 (Compound Cpd14) is an orally effective inhibitor of the BRG1/BRM enzyme domain. It exerts antitumor effects by disrupting aberrant chromatin remodeling in cancer cells, inducing apoptosis, and causing growth arrest. This compound is promising for research on BRG1/BRM-dependent malignancies, including hematologic cancers, prostate cancer, breast cancer, and Ewing's sarcoma.

BRM/BRG1 ATP degrader-1 (Compound 1) is a degrader of BRG1/BRM, with IC50 values of 0.01-0.1 μM for BRM IF degradation and greater than 0.1 μM for BRG1 IF degradation. This compound is applicable in cancer research studies.

Arg12-AHX is a synthetic ligand-linker conjugate for E3 ligase, utilized in synthesizing PROTACs like PROTACPLK1 Degrader-2. This compound, PROTACPLK1 Degrader-2, functions as a PLK1 PROTAC degrader with anti-tumor activity.

ARG1-IN-1 is a human arginase 1 inhibitor with an IC 50 of 29 nM.

BRM/BRG1 ATP Inhibitor-2 is a BRG1/BRM ATPase inhibitor, suitable for studies on the treatment of BAF-related disorders.